Ustekinumab-induced leukocytoclastic vasculitis in a young male with Crohn's disease
Ustekinumab-induced Leukocytoclastic Vasculitis in a Young Male with Crohn's disease (Source: Digestive and Liver Disease)
Source: Digestive and Liver Disease - March 24, 2024 Category: Gastroenterology Authors: Xiao-Peng Zhang, Huan Wang, Liang-ru Zhu Tags: Image of the Month Source Type: research
Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies
ConclusionAcross both clinical studies and real-world settings, more patients treated with IXE achieved NPF target and acceptable responses at week 12 compared with those treated with other biologics.Trial RegistrationUNCOVER-2 (NCT01597245); UNCOVER-3 (NCT01646177); IXORA-R (NCT03573323); IXORA-S (NCT02561806); PSoHO (EUPAS24207). (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - March 23, 2024 Category: Dermatology Source Type: research
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis
CONCLUSION: The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA.PMID:38503473 | DOI:10.1136/ard-2024-225534 (Source: Herpes)
Source: Herpes - March 19, 2024 Category: Infectious Diseases Authors: Andreas Kerschbaumer Josef S Smolen Ricardo J O Ferreira Heidi Bertheussen Xenofon Baraliakos Daniel Aletaha Dennis G McGonagle D ésirée van der Heijde Iain B McInnes Bente Appel Esbensen Kevin L Winthrop Wolf-Henning Boehncke Jan W Schoones Laure Gosse Source Type: research
Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero
Vedolizumab and ustekinumab pharmacokinetics in pregnancy and the infant following in-utero exposure remain incompletely defined. We aim to define the antenatal stability of ustekinumab and vedolizumab levels and the time at which infant drug levels become undetectable. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - March 14, 2024 Category: Gastroenterology Authors: Ralley Prentice, Emma Flanagan, Emily K. Wright, Peter R. Gibson, Sam Rosella, Ourania Rosella, Jakob Begun, Yoon-Kyo An, Ian C. Lawrance, Michael A. Kamm, Miles Sparrow, Rimma Goldberg, Lani Prideaux, Sara Vogrin, Katerina V. Kiburg, Alyson L. Ross, Mega Source Type: research
Biologics for Psoriasis
Biologic therapies targeting tumor necrosis factor alpha (TNF- α) (infliximab, adalimumab, certolizumab, etanercept), the p40 subunit shared by IL-12 and IL-23 (ustekinumab), the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab), IL-17A (secukinumab, ixekizumab), IL-17-RA (brodalumab) and both IL-17A and IL-17F (bimekizumab) have revolutionized th e treatment of psoriasis. In both the short and long term, risankizumab had highest Psoriasis Area and Severity Index 90 scores compared to other oral and injectable biologics. IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most fav...
Source: Dermatologic Clinics - March 13, 2024 Category: Dermatology Authors: Anthony Mitchel Wride, Gloria F. Chen, Sarah L. Spaulding, Elizabeth Tkachenko, Jeffrey M. Cohen Source Type: research
Cytomegalovirus Colitis in a Patient with Severe Treatment Refractory Ulcerative Colitis
CONCLUSIONS: Despite our patient having multiple risk factors for developing CMV colitis, upadacitinib may have played a role when considering its known impact on the herpes family of viruses. CMV colitis should be evaluated for in any patient who presents with worsening symptoms without evidence of other infection or response to increase in therapy.PMID:38444641 | PMC:PMC10914341 | DOI:10.1093/crocol/otae014 (Source: Herpes)
Source: Herpes - March 6, 2024 Category: Infectious Diseases Authors: Michelle M Bao Juliana M Kennedy Michael T Dolinger David Dunkin Joanne Lai Marla C Dubinsky Source Type: research
Cytomegalovirus Colitis in a Patient with Severe Treatment Refractory Ulcerative Colitis
CONCLUSIONS: Despite our patient having multiple risk factors for developing CMV colitis, upadacitinib may have played a role when considering its known impact on the herpes family of viruses. CMV colitis should be evaluated for in any patient who presents with worsening symptoms without evidence of other infection or response to increase in therapy.PMID:38444641 | PMC:PMC10914341 | DOI:10.1093/crocol/otae014 (Source: Herpes)
Source: Herpes - March 6, 2024 Category: Infectious Diseases Authors: Michelle M Bao Juliana M Kennedy Michael T Dolinger David Dunkin Joanne Lai Marla C Dubinsky Source Type: research
Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis
ConclusionAmong all available biologics and small-molecule inhibitors, secukinumab 300 mg and guselkumab 100 mg had the most favorable efficacy in treating PP and PPP, respectively. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - March 4, 2024 Category: Dermatology Source Type: research
Deep analysis of skin molecular heterogeneities and their significance on the precise treatment of patients with psoriasis
ConclusionsPsoriasis patients can be assorted into three subtypes with different molecular and cellular characteristics based on the heterogeneity of the skin's immune cells and the stroma, determining the clinical responses of conventional therapies. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - March 1, 2024 Category: Allergy & Immunology Source Type: research
Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials
ConclusionsIPD analysis demonstrated that both guselkumab doses were superior to ustekinumab for ACR 20 from weeks 16 (biologic-na ïve) and 24 (biologic-experienced) onwards, and for PASI 90 at weeks 16 and 52 for both subgroups. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 28, 2024 Category: Rheumatology Source Type: research
Research progress of Ustekinumab in the treatment of inflammatory bowel disease
Inflammatory bowel disease (IBD) is a chronic, recurrent gastrointestinal disorder with elusive etiology. Interleukin-12 (IL-12) and IL-23 have emerged as key proinflammatory mediators/cytokines in IBD pathogenesis. Ustekinumab (UST), targeting IL-12 and IL-23, has demonstrated promising efficacy and safety in the treatment of IBD. Recently, UST has become increasingly favored as a potential first-line treatment option. This review delineates UST’s mechanism of action, its clinical applications in IBD, including the response rates, strategies for dose optimization for case of partial or lost response, and potential adver...
Source: Frontiers in Immunology - February 22, 2024 Category: Allergy & Immunology Source Type: research
Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Crohn's Disease Patients Who Failed Anti-tumor Necrosis Factor- α Treatment in Japan: An Observational Study Utilizing Claims Database
This study aimed to investigate whether the approved sequence of vedolizumab and ustekinumab impacts the results of previous observational studies conducted in the European Union (EU), comparing the effectiveness of these drugs in Crohn's disease (CD) patients who failed anti-tumor necrosis factor-α (TNFα) treatment. We conducted this study in Japan, where the approved sequence of drugs is different from that of the EU. We extracted 256 patients diagnosed with CD, who had a history of anti-TNFα treatment and were prescribed either vedolizumab or ustekinumab, from JMDC claims database. The patients' backgrounds were adju...
Source: Biological and Pharmaceutical Bulletin - February 18, 2024 Category: Drugs & Pharmacology Authors: Minoru Shimazaki Yutaka Matsuyama Daisuke Koide Source Type: research
Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Crohn's Disease Patients Who Failed Anti-tumor Necrosis Factor- α Treatment in Japan: An Observational Study Utilizing Claims Database
This study aimed to investigate whether the approved sequence of vedolizumab and ustekinumab impacts the results of previous observational studies conducted in the European Union (EU), comparing the effectiveness of these drugs in Crohn's disease (CD) patients who failed anti-tumor necrosis factor-α (TNFα) treatment. We conducted this study in Japan, where the approved sequence of drugs is different from that of the EU. We extracted 256 patients diagnosed with CD, who had a history of anti-TNFα treatment and were prescribed either vedolizumab or ustekinumab, from JMDC claims database. The patients' backgrounds were adju...
Source: Biological and Pharmaceutical Bulletin - February 18, 2024 Category: Drugs & Pharmacology Authors: Minoru Shimazaki Yutaka Matsuyama Daisuke Koide Source Type: research
Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Crohn's Disease Patients Who Failed Anti-tumor Necrosis Factor- α Treatment in Japan: An Observational Study Utilizing Claims Database
This study aimed to investigate whether the approved sequence of vedolizumab and ustekinumab impacts the results of previous observational studies conducted in the European Union (EU), comparing the effectiveness of these drugs in Crohn's disease (CD) patients who failed anti-tumor necrosis factor-α (TNFα) treatment. We conducted this study in Japan, where the approved sequence of drugs is different from that of the EU. We extracted 256 patients diagnosed with CD, who had a history of anti-TNFα treatment and were prescribed either vedolizumab or ustekinumab, from JMDC claims database. The patients' backgrounds were adju...
Source: Biological and Pharmaceutical Bulletin - February 18, 2024 Category: Drugs & Pharmacology Authors: Minoru Shimazaki Yutaka Matsuyama Daisuke Koide Source Type: research
